A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Reversal on Moderna's flu application follows atypical path through FDA
Reversal on Moderna's flu application follows atypical path through FDA
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Faeth goes public in merger with Sensei, nets $200M in stock sale
Faeth goes public in merger with Sensei, nets $200M in stock sale
FDA reverses course, will review Moderna’s flu vaccine
FDA reverses course, will review Moderna’s flu vaccine
Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront
Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront
Paragon's new biotech Korsana tackles Alzheimer's like Roche
Paragon's new biotech Korsana tackles Alzheimer's like Roche
Leo Pharma says it's turned a profit for the first time in seven years
Leo Pharma says it's turned a profit for the first time in seven years
Moderna faces setback in Arbutus' mRNA patent fight
Moderna faces setback in Arbutus' mRNA patent fight
Unlocking health data
Unlocking health data
FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher
FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher
Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters
Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters
Compass Pathways soars on second Phase 3 depression hit
Compass Pathways soars on second Phase 3 depression hit
Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink
Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
Gilead gets cancer drug from China-based Genhouse for $80M upfront
Gilead gets cancer drug from China-based Genhouse for $80M upfront
Pentagon adds, then withdraws, WuXi AppTec to Chinese military list
Pentagon adds, then withdraws, WuXi AppTec to Chinese military list
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page